Interplay between fibrinolysis and complement: Plasmin cleavage of iC3b modulates immune responses

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 4, 2015, Pages 610-618

  Foley, J H ^a,b   Peterson, E A ^a,b   Lei, V ^a,b   Wan, L W ^a   Krisinger, M J ^a,c   Conway, E M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Complement; Fibrinolysis; IL 12; Inflammation; Innate immunity; Macrophage

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D; COMPLEMENT FACTOR H; FIBRINOGEN; INTERLEUKIN 12; OPSONIN; PLASMIN; PLASMINOGEN; ZYMOSAN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AUTACOID; COMPLEMENT C3D,G; PEPTIDE FRAGMENT;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; COVALENT BOND; CYTOKINE RELEASE; ERYTHROCYTE; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; ANIMAL; CELL LINE; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; RABBIT; SIGNAL TRANSDUCTION; TIME FACTOR;

ANIMALS; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY; COMPLEMENT C3B; FIBRINOLYSIN; FIBRINOLYSIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTERLEUKIN-12; MACROPHAGES; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; PROTEOLYSIS; RABBITS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84926086856     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12837     Document Type: Article

References (34)

1. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Bruckner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185: 5628-36.
2. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement-their role in inflammation. Semin Immunopathol 2012; 34: 151-65.
3. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol 2014; 32: 433-59.
4. Speidl WS, Kastl SP, Huber K, Wojta J. Complement in atherosclerosis: friend or foe? J Thromb Haemost 2011; 9: 428-40.
5. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-97.
6. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998; 188: 2313-20.
7. Torok K, Kremlitzka M, Sandor N, Toth EA, Bajtay Z, Erdei A. Human T cell derived, cell-bound complement iC3b is integrally involved in T cell activation. Immunol Lett 2012; 143: 131-6.
8. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity 2012; 37: 199-207.
9. Davis AE 3rd, Harrison RA, Lachmann PJ. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d, g (alpha 2D), and C3 g. J Immunol 1984; 132: 1960-6.
10. Bergmann-Leitner ES, Leitner WW, Tsokos GC. Complement 3d: from molecular adjuvant to target of immune escape mechanisms. Clin Immunol 2006; 121: 177-85.
11. Nagasawa S, Stroud RM. Mechanism of action of the C3b inactivator: requirement for a high molecular weight cofactor (C3b-C4bINA cofactor) and production of a new C3b derivative (C3b'). Immunochemistry 1977; 14: 749-56.
12. Lachmann PJ, Pangburn MK, Oldroyd RG. Breakdown of C3 after complement activation. Identification of a new fragment C3 g, using monoclonal antibodies. J Exp Med 1982; 156: 205-16.
13. Seya T, Nagasawa S, Matsukura M, Hasegawa H, Atkinson JP. Generation of C3d, g and C3d by urokinase-treated plasma in association with fibrinolysis. Complement 1985; 2: 165-74.
14. Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, Lambris JD, Huber-Lang M. Interaction between the coagulation and complement system. Adv Exp Med Biol 2008; 632: 71-9.
15. Barthel D, Schindler S, Zipfel PF. Plasminogen is a complement inhibitor. J Biol Chem 2012; 287: 18831-42.
16. Krisinger MJ, Goebeler V, Lu Z, Meixner SC, Myles T, Pryzdial EL, Conway EM. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012; 120: 1717-25.
17. Sweeney WM. Aminocaproic acid, an inhibitor of fibrinolysis. Am J Med Sci 1965; 249: 576-89.
18. Takizawa F, Tsuji S, Nagasawa S. Enhancement of macrophage phagocytosis upon iC3b deposition on apoptotic cells. FEBS Lett 1996; 397: 269-72.
19. Gu L, Ning H, Qian X, Huang Q, Hou R, Almourani R, Fu M, Blackshear PJ, Liu J. Suppression of IL-12 production by tristetraprolin through blocking NF-kcyB nuclear translocation. J Immunol 2013; 191: 3922-30.
20. Marth T, Kelsall BL. Regulation of interleukin-12 by complement receptor 3 signaling. J Exp Med 1997; 185: 1987-95.
21. Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol 1982; 129: 2051-60.
22. Harrison RA, Lachmann PJ. The physiological breakdown of the third component of human complement. Mol Immunol 1980; 17: 9-20.
23. Silverstein RL, Friedlander RJ Jr, Nicholas RL, Nachman RL. Binding of Lys-plasminogen to monocytes/macrophages. J Clin Investig 1988; 82: 1948-55.
24. Ly D, Taylor JM, Tsatsaronis JA, Monteleone MM, Skora AS, Donald CA, Maddocks T, Nizet V, West NP, Ranson M, Walker MJ, McArthur JD, Sanderson-Smith ML. Plasmin(ogen) acquisition by group A Streptococcus protects against C3b-mediated neutrophil killing. J Innate Immun 2014; 6: 240-50.
25. Koch TK, Reuter M, Barthel D, Bohm S, van den Elsen J, Kraiczy P, Zipfel PF, Skerka C. Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b. PLoS ONE 2012; 7: e47638.
26. Toapanta FR, Ross TM. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 2006; 36: 197-210.
27. van Lookeren Campagne M, Wiesmann C, Brown EJ. Macrophage complement receptors and pathogen clearance. Cell Microbiol 2007; 9: 2095-102.
28. Frey A, Ertl G, Angermann CE, Hofmann U, Stork S, Frantz S. Complement C3c as a biomarker in heart failure. Mediators Inflamm 2013; 2013: 716902.
29. Torzewski M, Bhakdi S. Complement and atherosclerosis-united to the point of no return? Clin Biochem 2013; 46: 20-5.
30. Huang J, Huffman JE, Yamkauchi M, Trompet S, Asselbergs FW, Sabater-Lleal M, Tregouet DA, Chen WM, Smith NL, Kleber ME, Shin SY, Becker DM, Tang W, Dehghan A, Johnson AD, Truong V, Folkersen L, Yang Q, Oudot-Mellkah T, Buckley BM, et al. Genome-wide association study for circulating tissue plasminogen activator levels and functional follow-up implicates endothelial STXBP5 and STX2. Arterioscler Thromb Vasc Biol 2014; 34: 1093-101.
31. Rossignol P, Luttun A, Martin-Ventura JL, Lupu F, Carmeliet P, Collen D, Angles-Cano E, Lijnen HR. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost 2006; 4: 664-70.
32. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen D, Carmeliet P. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2002; 22: 499-505.
33. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005; 25: 2255-64.
34. Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK, Warrier RR, Pham N, Fogelman AM, Modlin RL. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Investig 1996; 97: 2130-8.